Literature DB >> 27006495

Neoantigen: A Long March toward Cancer Immunotherapy.

Yang Liu1.   

Abstract

Somatic mutations in cancer give rise to neoantigens. Technology revolutions in cancer genomics and immunology have made it possible to rapidly identify neoantigens for cancer vaccines. Leisegang and colleagues report that it is practical to rapidly identify neoantigens for adoptive T-cell therapy in a mouse tumor model. Clin Cancer Res; 22(11); 2602-4. ©2016 AACRSee related article by Leisegang et al., p. 2734. ©2016 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27006495      PMCID： PMC4891220          DOI： 10.1158/1078-0432.CCR-15-3170

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  13 in total

1.  Antigenic drift as a mechanism for tumor evasion of destruction by cytolytic T lymphocytes.

Authors:  Xue-Feng Bai; Jinqing Liu; Ou Li; Pan Zheng; Yang Liu
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

2.  The immunodominant antigen of an ultraviolet-induced regressor tumor is generated by a somatic point mutation in the DEAD box helicase p68.

Authors:  P Dubey; R C Hendrickson; S C Meredith; C T Siegel; J Shabanowitz; J C Skipper; V H Engelhard; D F Hunt; H Schreiber
Journal:  J Exp Med       Date:  1997-02-17       Impact factor: 14.307

3.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.

Authors:  P van der Bruggen; C Traversari; P Chomez; C Lurquin; E De Plaen; B Van den Eynde; A Knuth; T Boon
Journal:  Science       Date:  1991-12-13       Impact factor: 47.728

Review 4.  Tumor antigens recognized by T lymphocytes.

Authors:  T Boon; J C Cerottini; B Van den Eynde; P van der Bruggen; A Van Pel
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

5.  Eradication of Large Solid Tumors by Gene Therapy with a T-Cell Receptor Targeting a Single Cancer-Specific Point Mutation.

Authors:  Matthias Leisegang; Boris Engels; Karin Schreiber; Poh Yin Yew; Kazuma Kiyotani; Christian Idel; Ainhoa Arina; Jaikumar Duraiswamy; Ralph R Weichselbaum; Wolfgang Uckert; Yusuke Nakamura; Hans Schreiber
Journal:  Clin Cancer Res       Date:  2015-12-14       Impact factor: 12.531

6.  Cytotoxic T lymphocytes to an unmutated tumor rejection antigen P1A: normal development but restrained effector function in vivo.

Authors:  S Sarma; Y Guo; Y Guilloux; C Lee; X F Bai; Y Liu
Journal:  J Exp Med       Date:  1999-03-01       Impact factor: 14.307

7.  The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice.

Authors:  B Van den Eynde; B Lethé; A Van Pel; E De Plaen; T Boon
Journal:  J Exp Med       Date:  1991-06-01       Impact factor: 14.307

8.  The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas.

Authors:  V Brichard; A Van Pel; T Wölfel; C Wölfel; E De Plaen; B Lethé; P Coulie; T Boon
Journal:  J Exp Med       Date:  1993-08-01       Impact factor: 14.307

9.  Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes.

Authors:  P Romero; P R Dunbar; D Valmori; M Pittet; G S Ogg; D Rimoldi; J L Chen; D Liénard; J C Cerottini; V Cerundolo
Journal:  J Exp Med       Date:  1998-11-02       Impact factor: 14.307

10.  Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity.

Authors:  Fei Duan; Jorge Duitama; Sahar Al Seesi; Cory M Ayres; Steven A Corcelli; Arpita P Pawashe; Tatiana Blanchard; David McMahon; John Sidney; Alessandro Sette; Brian M Baker; Ion I Mandoiu; Pramod K Srivastava
Journal:  J Exp Med       Date:  2014-09-22       Impact factor: 14.307
View more
  3 in total

1.  Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies.

Authors:  Ryan J Hartmaier; Jehad Charo; David Fabrizio; Michael E Goldberg; Lee A Albacker; William Pao; Juliann Chmielecki
Journal:  Genome Med       Date:  2017-02-24       Impact factor: 11.117

Review 2.  Neoantigen vaccine: an emerging tumor immunotherapy.

Authors:  Miao Peng; Yongzhen Mo; Yian Wang; Pan Wu; Yijie Zhang; Fang Xiong; Can Guo; Xu Wu; Yong Li; Xiaoling Li; Guiyuan Li; Wei Xiong; Zhaoyang Zeng
Journal:  Mol Cancer       Date:  2019-08-23       Impact factor: 27.401

3.  Using T-cell repertoire profiles as predictor in a primary mucosal melanoma.

Authors:  Che-Mai Chang; Yu-Ming Liao; Gong-Yau Lan; Wei-Chiao Chang; Yun Yen
Journal:  Clin Transl Med       Date:  2020-08-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.